Reversal to Normoglycemia by Treating Prediabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 158 participants.

Also called NCT07392151

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 158 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07392151
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07392151. Randomized; no masking; primary purpose prevention. Start 2026-02 (anticipated); primary completion 2029-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Reversal to Normoglycemia by Treating Prediabetes
Condition
Prediabetes
Condition
Chronic Coronary Syndrome
Intervention (Drug)
Intensified medical follow-up and glucose-lowering drugs
Intervention (Other)
No intervention
Lead sponsor
Michael Mæng (class: other)
Collaborator
Aarhus University Hospital (class: other)
Collaborator
GCP-unit at Aarhus University Hospital, Aarhus, Denmark (class: other)
Collaborator
Department of Clinical Epidemiology, Aarhus University, DK-8200 Aarhus N, Denmark (class: not stated)
Collaborator
University of Aarhus (class: other)

Record details

Record id
cardio:ct-nct07392151
Content hash
b351720761eb408eceb3c79f561e016d70da2bb965c848149e6c851b64a69c74